Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings

References

• AASLD-IDSA Hepatitis C Guidance Panel. (2020). Hepatitis C guidance 2019 update: American Association for the study of liver diseases–infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology, 71(2), 686–721.
   PubMed Web of Science ®Google Scholar
• Alderks, C. E. (2017). TRENDS IN THE USE OF METHADONE,BUPRENORPHINE, AND EXTENDED-RELEASE NALTREXONE AT SUBSTANCE ABUSE TREATMENT FACILITIES: 2003-2015 (UPDATE). Retrieved from https://www.samhsa.gov/data/sites/default/files/report_3192/ShortReport-3192.pdf
   Google Scholar
• American Society of Addiction Medicine (2018). Public Policy Statement on the Regulation of Office-Based Opioid Treatment. Rockville.
   Google Scholar
• Carey, K. J., Huang, W., Linas, B. P., & Tsui, J. I. (2016). Hepatitis C virus testing and treatment among persons receiving buprenorphine in an office-based program for opioid use disorders. Journal of Substance Abuse Treatment, 66, 54–59. https://doi.org/10.1016/j.jsat.2016.01.009
   PubMed Web of Science ®Google Scholar
• CDC (2018). Hepatitis C Questions and Answers for Health Professionals. Retrieved from https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#Ref09
   Google Scholar
• Degenhardt, L., Peacock, A., Colledge, S., Leung, J., Grebely, J., Vickerman, P., Stone, J., Cunningham, E. B., Trickey, A., Dumchev, K., Lynskey, M., Griffiths, P., Mattick, R. P., Hickman, M., & Larney, S. (2017). Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. The Lancet. Global Health, 5(12), e1192–e1207. https://doi.org/10.1016/S2214-109X(17)30375-3
   PubMed Web of Science ®Google Scholar
• Duff, J. H., Carter, J. A. (2019). Location of Medication-Assisted Treatment for Opioid Addiction: In Brief. Retrieved from https://fas.org/sgp/crs/misc/R45782.pdf
   Google Scholar
• Edlin, B. R., Eckhardt, B. J., Shu, M. A., Holmberg, S. D., & Swan, T. (2015). Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology (Baltimore, Md.), 62(5), 1353–1363. https://doi.org/10.1002/hep.27978
   PubMed Web of Science ®Google Scholar
• Fingerhood, M. I., King, V. L., Brooner, R. K., & Rastegar, D. A. (2014). A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment. Substance Abuse, 35(2), 122–126. https://doi.org/10.1080/08897077.2013.819828
   PubMed Web of Science ®Google Scholar
• Flanigan, C. A., Leung, S.-Y J., Rowe, K. A., Levey, W. K., King, A., Sommer, J. N., Morne, J. E., & Zucker, H. A. (2017). Evaluation of the impact of mandating health care providers to offer hepatitis C virus screening to all persons born during 1945-1965 - New York, 2014. MMWR. Morbidity and Mortality Weekly Report, 66(38), 1023–1026. https://doi.org/10.15585/mmwr.mm6638a3
   PubMed Web of Science ®Google Scholar
• Frimpong, J. A. (2013). Missed opportunities for hepatitis C testing in opioid treatment programs. American Journal of Public Health, 103(6), 1028–1030. https://doi.org/10.2105/AJPH.2012.301129
   PubMed Web of Science ®Google Scholar
• Frimpong, J. A., D'Aunno, T., & Jiang, L. (2014). Determinants of the availability of hepatitis C testing services in opioid treatment programs: Results from a national study. American Journal of Public Health, 104(6), e75–e82. https://doi.org/10.2105/AJPH.2013.301827
   PubMed Web of Science ®Google Scholar
• Gordon, A. J., Lo-Ciganic, W. H., Cochran, G., Gellad, W. F., Cathers, T., Kelley, D., & Donohue, J. M. (2015). Patterns and quality of buprenorphine opioid agonist treatment in a large Medicaid program. Journal of Addiction Medicine, 9(6), 470–477. https://doi.org/10.1097/ADM.0000000000000164
   PubMed Web of Science ®Google Scholar
• Hadland, S. E., Wharam, J. F., Schuster, M. A., Zhang, F., Samet, J. H., & Larochelle, M. R. (2017). Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatrics, 171(8), 747–755. https://doi.org/10.1001/jamapediatrics.2017.0745
   PubMed Web of Science ®Google Scholar
• Hansen, H., Siegel, C., Wanderling, J., & DiRocco, D. (2016). Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug and Alcohol Dependence, 164, 14–21. https://doi.org/10.1016/j.drugalcdep.2016.03.028
   PubMed Web of Science ®Google Scholar
• Havens, P. L., & Anderson, J. R. (2020). Updated CDC recommendations for universal hepatitis C virus screening among adults and pregnant women: Implications for clinical practice. JAMA, 323(22), 2258–2259. https://doi.org/10.1001/jama.2020.3693
   PubMed Web of Science ®Google Scholar
• Isenhour, C. J., Hariri, S. H., Hales, C. M., & Vellozzi, C. J. (2017). Hepatitis C antibody testing in a commercially insured population, 2005-2014. American Journal of Preventive Medicine, 52(5), 625–631. https://doi.org/10.1016/j.amepre.2016.12.016
   PubMed Web of Science ®Google Scholar
• Korthuis, P. T., McCarty, D., Weimer, M., Bougatsos, C., Blazina, I., Zakher, B., Grusing, S., Devine, B., & Chou, R. (2017). Primary care–based models for the treatment of opioid use disorder: A scoping review. Annals of Internal Medicine, 166(4), 268–278. https://doi.org/10.7326/M16-2149
   PubMed Web of Science ®Google Scholar
• Linas, B. P., Hu, H., Barter, D. M., & Horberg, M. (2014). Hepatitis C screening trends in a large integrated health system. The American Journal of Medicine, 127(5), 398–405. https://doi.org/10.1016/j.amjmed.2014.01.012
   PubMed Web of Science ®Google Scholar
• Ly, K. N., Hughes, E. M., Jiles, R. B., & Holmberg, S. D. (2016). Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 62(10), 1287–1288. https://doi.org/10.1093/cid/ciw111
   PubMed Web of Science ®Google Scholar
• NYSDOH (2013). NYS Hepatitis C Testing Law Frequently Asked Questions. Retrieved from https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/rapid_antibody_testing/faqs.htm
   Google Scholar
• OASAS (2017). Part 822 - General Service Standards for Chemcial Dependence Outpatient (CD-OP) and Opioid Treatment Programs (OTP). Retrieved from https://www.oasas.ny.gov/regs/documents/Part822GeneralServiceStandardsforChemicalDependenceOutpatientandOpioidTreatmentPrograms.pdf
   Google Scholar
• OASAS (2018). Correcting Common Misunderstandings Regarding Methadone, Buprenorphine and Naltrexone. Retrieved from https://www.oasas.ny.gov/admed/fyi/misunderstanding-FYI.cfm
   Google Scholar
• Polydorou, S., Ross, S., Coleman, P., Duncan, L., Roxas, N., Thomas, A., Mendoza, S., & Hansen, H. (2017). Integrating buprenorphine into an opioid treatment program: Tailoring care for patients with opioid use disorders. Psychiatric Services (Washington, D.C.).), 68(3), 295–298. https://doi.org/10.1176/appi.ps.201500501
   PubMed Web of Science ®Google Scholar
• Roblin, D. W., Smith, B. D., Weinbaum, C. M., & Sabin, M. E. (2011). HCV screening practices and prevalence in an MCO, 2000-2007. Am J Manag Care, 17(8), 548–555. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21851142
   PubMed Web of Science ®Google Scholar
• SAMHSA (2015). Federal Guidelines for Opiod Treatment Programs. Substance Abuse and Mental Health Services Administration Retrieved from https://store.samhsa.gov/shin/content/PEP15-FEDGUIDEOTP/PEP15-FEDGUIDEOTP.pdf
   Google Scholar
• Sayas, A., McKay, S., Honermann, B., Blumenthal, S., Millett, G., Jones, A. (2018). Despite Infectious Disease Outbreaks Linked To Opioid Crisis, Most Substance Abuse Facilities Don’t Test For HIV Or HCV. Retrieved from https://www.healthaffairs.org/do/10.1377/hblog20181002.180675/full/
   Google Scholar
• Schillie, S., Wester, C., Osborne, M., Wesolowski, L., & Ryerson, A. B. (2020). CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR. Recommendations and Reports, 69(2), 1–17. https://doi.org/10.15585/mmwr.rr6902a1
   Web of Science ®Google Scholar
• Shatin, D., Schech, S. D., Patel, K., & McHutchison, J. G. (2004). Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care, 10(4), 250–256. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15124501
   PubMed Web of Science ®Google Scholar
• Smith, B. D., Morgan, R. L., Beckett, G. A., Falck-Ytter, Y., Holtzman, D., Teo, C. G. … Prevention., (2012). Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep, 61(RR-4), 1–32. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22895429
   PubMedGoogle Scholar
• Trager, E., Khalili, M., Masson, C. L., Vittinghoff, E., Creasman, J., & Mangurian, C. (2016). Hepatitis C screening rate among underserved adults with serious mental illness receiving care in California community mental health centers. American Journal of Public Health, 106(4), 740–742. https://doi.org/10.2105/AJPH.2016.303059
   PubMed Web of Science ®Google Scholar
• USPSTF (2016). Final Recommendation Statement: Hepatitis C: Screening. U.S. Preventive Services Task Force. Retrieved from https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/hepatitis-c-screening
   Google Scholar
• Younossi, Z., Gordon, S. C., Ahmed, A., Dieterich, D., Saab, S., & Beckerman, R. (2017). Treating Medicaid patients with hepatitis C: Clinical and economic impact. The American Journal of Managed Care, 23(2), 107–112. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28245654
   PubMed Web of Science ®Google Scholar
• Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B., Iqbal, K., Ward, J. W., & Holtzman, D. (2018). Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. American Journal of Public Health, 108(2), 175–181. https://doi.org/10.2105/AJPH.2017.304132
   PubMed Web of Science ®Google Scholar